secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001434647-26-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra reports Q4 net revenue $34.1M, net income $12.2M; appoints Justin Renz as CFO
--------------------------------------------------------------------------------

- Q4 2025 net revenue $34.1M (+31% QoQ); net income $12.2M ($0.19 diluted EPS) vs. $(35.7)M loss in Q4 2024.
- FY 2025 net revenue $106.5M (MIPLYFFA $87.4M); net income $83.2M ($1.35 diluted EPS) vs. $(105.5)M loss in FY 2024.
- MIPLYFFA: 24 new prescription enrollment forms in Q4; 52 in 2025; 161 since launch; EU MAA under EMA review, 120-day questions received.
- Justin Renz appointed CFO effective March 9, 2026; base salary $520k, 45% target bonus, option grant of 300k shares vesting over 4 years.
- Cash, cash equivalents and securities $238.9M at year-end; 56.9M common shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000009/0001434647-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000009/zvra-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001434647-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer